Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Med-tech company, HeraMED has received FDA clearance for its HeraBEAT device
  • HeraBEAT is an ultrasonic heart rate monitor for unborn babies. The device allows expecting mothers to monitors their baby’s heart activity, in the comfort of their own home
  • The United States is a huge market for HeraBeat, as roughly four million pregnancies occur annually
  • HeraMED is up 27 per cent on the market this morning, trading at 28 cents apiece

HeraMED has received a U.S. food and drug administration (FDA) clearance for its HeraBEAT device.

HeraBEAT is an ultrasonic heart rate monitor for unborn babies. The device allows pregnant women to check on their baby, in the comfort of their own home.

Expecting parents can pair the device with their smartphones to monitor the baby’s heart beat and heart rate.

The handheld HeraBEAT device includes an ultrasound transducer, rechargeable battery and internal micro-controller, and a Bluetooth Low Energy (BLE) chip for wireless data that connects the device to the user’s smartphone.

Receiving this clearance for the HeraBEAT device now allows the product to be commercially distributed throughout the United States. The company said it will begin distribution as quickly as possible.

CEO David Groberman is pleased with receiving FDA clearance and says it is a tremendous achievement for HeraMED.

“The device development and testing, providing substantial evidence of the safety and effectiveness of the device, has passed a challenging and rigorous period of review by FDA and is now ready for distribution throughout the United States in the coming months,” David said.

“It will liaise with its in-country partners, to ensure that the process is as streamlined as possible,” he added.

The United States is a huge market for HeraBeat, in which approximately four million pregnancies occur annually. The company is confident the device will be well received in the U.S. market.

Just last month, the company announced it was progressing with HeraBEAT and HeraCARE in India which

HeraMED is up 27 per cent on the market this morning, trading at 28 cents apiece at 11:49 am AEDT.

HMD by the numbers
More From The Market Herald
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) secures new licences in Q3 amid revenue slump

ResApp Health (RAP) has released its quarterly activities report for the three months to the end of September 2021.

" Incannex Healthcare (ASX:IHL) lands ethics approval for psychedelic-based anxiety treatment trial

Incannex Healthcare (IHL) has spiked on the ASX today after landing important regulatory approvals to trial a psychedelic-based treatment for severe anxiety.

" Rhinomed (ASX:RNO) receives ethics approval for Rhinoswab trial

Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.